Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions

Inclusion Criteria: * Males and females aged 18-85 years who had given written informed consent. * Subjects with a body mass index within 15 to 35 kg/m2. * Subjects with clinically acceptable results for the laboratory tests * Female subjects of child bearing potential who are using acceptable method(s) of contraception. Exclusion Criteria: * Subjects with history or evidence of hypertrophic or keloid scarring. * Subjects with tattoos or previous scars within 3cm of the area to be incised. * Subjects with prior surgery in the area to be incised within one year of the first dosing day. * Subjects with a history of a bleeding disorder; receiving anti-coagulant or anti-platelet therapy. * Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial. * Subjects with a clinically significant skin disorder that is chronic or currently active. * Subjects with any clinically significant medical condition or history that would impair wound healing. * Subjects with a history of drug hypersensitivity to any of the drugs or dressings used in this trial. * Subjects who are taking, or have taken any investigational product or participated in a clinical trial in the three months prior to first trial dose administration. * Subjects who are taking regular, continuous, oral corticosteroid therapy. * Subjects undergoing investigations or changes in management for an existing medical condition. * Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, metamphetamines, opiates or benzodiazepines during the screening period. * Subjects who are considered unlikely to complete the trial for whatever reason. * Subjects with a clinically significant neurological impairment or disease. * Subjects with any active infection. * Subjects who are pregnant or lactating.